Qexd (@Qexd) header
Qexd (@Qexd) profile picture

BGAN Collectoooooor

Joined January 2012
Photo by Qexd (@Qexd)Photo by Qexd (@Qexd)Photo by Qexd (@Qexd)Photo by Qexd (@Qexd)Photo by Qexd (@Qexd)Photo by Qexd (@Qexd)Photo by Qexd (@Qexd)Photo by Qexd (@Qexd)Photo by Qexd (@Qexd)Photo by Qexd (@Qexd)
RVMD - Best in disease efficacy drugs in life threatening or serious diseases don’t need marketing. Patients and families come running asking for it. It’s 2026.
3
3
1
76
5,494
Since people are talking about target crowding, here's a chart from an upcoming post: <5% of new drugs entering the clinic are going after targets that haven't been tested clinically before, ~60% are going after targets with an approved drug. New ideas are hard to find!
The Fruits of AI Drug Abundance: Indigestion In The Near Term While the long term impact of AI is likely transformational, in the near term more drugs against known targets will likely exacerbate the crowding challenge dragging down industry R&D productivity lifescivc.com/2026/10/the-fr…
8
24
8
141
21,837
Every month since April has had more crypto hacks than any month prior to April.
17
12
8
132
16,354
Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own. In doing so, we’ve learned much more about how Claude can support the many stages of drug development. In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences. anthropic.com/research/early…
777
1,334
704
11,920
3,686,290
Croatian philosopher and priest Ivan Illich in a speech in Tokyo in 1982 on silence as a commons, now transformed into a valuable resource.
4
38
6
177
ESMO 2026 kicks off later this week - we analyzed thousands of abstracts and pulled out 8 themes that stood out to us heading into the conference. • Something fundamental about oncology is that every time a drug moves earlier in treatment, it changes the downstream patient population (and the competitive landscape), creating new opportunities for differentiation. We see that theme coming up in a few areas this year, with EV + pembro in bladder cancer and HER2-directed ADCs in breast cancer moving earlier. Frontline treatments tend to be more durable in holding their position in the treatment sequence, so being able to anticipate these shifts as pivotal data emerges is a huge advantage. Send me a message if you'd like this analysis done for a space you're tracking closely. • One of the best parts of ESMO is getting to peer into the future - there's often a big disconnect between current late-stage trials and where early-stage efforts are accumulating. For example in KRAS, ~76% of clinical KRAS abstracts involve combinations, versus just 1 in 4 ongoing Ph3 programs. Development competition is split between two approaches: selectively target the dominant mutant (G12D) vs. inhibit a broader set of RAS-driven tumors (daraxonrasib). All things equal, the latter is a better opportunity, so the debate is where precision might beat breadth. • China is dominating ADC innovation, with ~86% of Ph3 readouts at ESMO coming from China-originated assets. Some are quite novel too, such as bispecific architectures (i.e. EGFR x HER3) Broadly, as ADCs have moved into earlier treatment settings, they've been benchmarked against non-ADC standards. As some settle in as frontline treatment, it's creating a resistance problem for next-gen assets: if payload resistance cuts across targets, then the Topo I concentration may 'poison the well' for ADCs still competing in later-line settings. The 12-page preview below gets into the details behind these and other themes, including key programs, data and references. Hope it's helpful for everyone heading to Madrid or following along remotely. Let us know in the comments what trends you're watching and if you'd like us to send the full PDF + some bonus data to you directly.
3
13
67
6,999
The problem of our time is not merely information overload. It is that the time required to construct a coherent understanding of reality is becoming longer than the time during which that understanding remains valid.
92
389
60
2,253
85,465
NEW ODD LOTS: It’s the podcast debut for Jeff Yan @tracyalloway and I have an ultra-rare interview with the CEO and co-founder of Hyperliquid Labs about his plan to house the world’s entire financial system open.spotify.com/episode/5Aq…
85
101
47
960
301,865
Qexd retweeted
Runescape Bench result - Gemini 4 Argon is legit! Very similar to Astra in performance, at a Sol price.
8
18
3
301
15,499
A Gaussian splat of a tiny plot in the forest. Mosses, sprouts, seeds, fungi, fir needles and a cone can all be seen on such a small area. #3dgs
6
23
1
178
3,602
🚨Our new research examines agentic shopping: can you consistently predict (or, using marketing, influence) what an agent chooses? Nope. We found that even small differences (viewing order of pages, memories) changed AI preferences in unpredictable ways. papers.ssrn.com/sol3/papers.…
42
29
8
201
31,382
Qexd retweeted
bot-only runescape server has multiple competing swarm armies fighting for control of the wilderness right now
29
37
7
1,567
82,918
10/ The takeaway: birdsong is vast but not endless. It settles into a small, finite set of sounds, set by a trade-off between saying more and travelling far.
1
8
57
1,511
Qexd retweeted
every single person i know working at the frontier is incredibly talented and hardworking, and they're not wasting compute or capital, and neither is america. some thoughts / opinions on this 1/ new capability is infinitely harder. i'm not saying chinese labs are just mass distilling (although there's some of that), but even a few teacher model calls to 5.6 sol pro for math or fable agent rollouts is OOMs cheaper than hiring human experts, sourcing data, cleaning data, etc. this is why mercor, scale and the other data vendors do so well. paying physics phds to help teach the models is not cheap, and china does indeed get a leg up here. this is also why i suspect most labs have the true frontier model internal only. the modus operandi seems to be to assume any model put into the hands of hyperscalers or released via api will be distilled or stolen. what the public sees is ~6 mo behind what's internal, and depending on how the chinese labs are operating, they're either ~1yr behind, or ~1.5yrs behind the true capability of the labs. there's also a fair amount of benchmaxxing from china, as they only have to show a good looking number to be considered great, not get sustained usage to stay alive (like the US labs), or be efficient at inference (which is also an optimization for the labs, more on this later). the modus operandi seems to be to assume any model put into the hands of hyperscalers or released via API will be distilled or stolen, which is 100% justified and right. talent and ip bleed is a also real thing. a lab may frequently have to run/burn thousands of tests to figure out the optimal config/architecture for a model. anyone on the training, inference team or one of the hyperscalers who hosts the model can just look at one model implementation/config file and know the truth and understand and replicate. you don't need to know what didn't work, only what did. 2/ data privacy requirements (or lack thereof) in mainland china. assuming reasonably that the six little tigers in china (look it up if you don't know about this) have access to some form of additional ccp data that we do not know about, it is a moderate advantage. the labs are incredibly thirsty for novel data. the internet has mostly exhausted its utility, at least with current techniques, and much like what ilya said, there is only one internet (like fossil fuels!). people are also deploying the models to things never seen before. i.e how is a model supposed to learn how to order food with the doordash cli unless its taught how to behave in this scenario / is superhuman at generalization. US enterprises are also vary of this, and therefore cannot and do not rely on chinese model apis. i don't think this is cope, although i realize many may feel this way 3/ inference efficiency: the modern labs are extremely good at inference. the gb300 is a beast, and even older chips are being used very well to serve the models. api pricing is meant to also recover the cost on training, and inference cost for intelligence continues to fall. all labs have really large sparse moes that are OOMs cheaper than what api pricing reflects. 4/ profit motive: there is an interesting dwarkesh podcast about this. you must stop looking at china from the worldview of they're trying to make money. this is just not true. they're trying to dominate via scale and volume, which is true for the way china works, but not the us. the people of china are incredible, extremely sharp and are not to be underestimated. 996 work culture and strong stem is a great source of talent and data for the labs. american labs must pay around $1m/yr for entry level talent in the bay, which also increases capex. also there's an undisclosed amount of capex coming from the ccp. i do not claim to know what the scale is, but i would suspect there's a fair amount of chips flowing through the gulf, khazakstan etc. (do we seriously believe khazakstan of all places is building $10B worth of datacenters with nvidia gpus all for/by themselves?) 5/ datacenter and build out. xai had to spend a lot of money, time and effort to build out the supercomputer in tennessee. anthropic pays them 10 digits to lease out to serve customers etc because of the lack of supply, electricity, zoning, regulation etc. ccp does not have this issue, and there are claims that they are indeed introducing misinformation into the us that data centers are bad for us. we have to get much much faster about addressing this and dealing with "muh water use" kind of statements. it's oneshotting our population, much like nuclear energy did. electricity is the final moat, over chips, models, intelligence, and data. regardless of your timelines, if you believe in rsi, then you know the physical world is the only bottleneck. china/the ccp has real, compounding structural edges on data access, deployment freedom, talent cost, speed of physical buildout, and now apparently on shaping the domestic narrative around our datacenters and energy. america is making the best use of it's most powerful resource, capital, to accelerate faster.
Replying to @lu_sichu
i do think that openai and anthropic need to answer for why they are barely 4 months ahead but are spending like 10x the capex of chinese labs (maybe an understatement)
34
77
16
765
235,624
Qexd retweeted
ChatGPT Sites is now in public beta. You can turn a prompt, file, or rough idea into a dashboard, project tracker, report, prototype, or lightweight app: build and edit directly in ChatGPT Work or Codex test in a private preview publish and share with a URL Rolling out across paid plans. Enterprise admins can control public publishing.
65
31
14
801
168,611
Slightly late, but here's some 2H catalysts with some notes. See images for Sell side catalyst trackers
11
28
4
214
36,179
Replying to @TheStalwart
The best right handed posters also scroll their phones with their left hands
1
2
30
8,483
this will become outdated in a year or less, but what are the most engaging resources out there for how to best setup agent workflows? especially in the context of data-sciency/researchy tasks? like any good youtube how-tos?
26
6
351
39,228
Cancer outcomes improve through iterative, stepwise progress that gradually updates the standard of care. A good example here in metastatic colorectal cancer:
5
17
1
60
7,311